Limited data exist on the extent of use of evidence-based SGLT2-is and GLP-1 RAs among recent real-world cohorts of patients with DM including underrepresented patient groups, and according to level of cardiovascular risk and sociodemographic factors. Here, SLC5A2 is linked to diabetes mellitus.